Market revenue in 2023 | USD 700.3 million |
Market revenue in 2030 | USD 1,046.9 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 47.38% in 2023. Horizon Databook has segmented the Asia Pacific neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is the fastest-growing market as many developed nations are investing in Asia Pacific region. The recruitment for clinical trials is increasing in Asia as compared to North America and Europe. This is due to the large patient pool & low trial cost.
Moreover, clinical research combined with experienced investigators & research teams is contributing to the market growth. Clinical research in the region is well-established, with many international pharmaceutical companies & CROs having been operating in the region for more than two decades.
There are also key opinion leaders and centers of excellence across various therapeutic areas in the region. The government is also making efforts to drive the neurology clinical trials market growth. It is allocating new resources for data collection & scientific infrastructure, strengthening the protection of intellectual property, and enhancing access to patient populations.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific neurology clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account